On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj ®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer ...
Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback